First filing for Daiichi Sankyo's inhaled flu drug
This article was originally published in Scrip
Daiichi Sankyo has filed for the approval in Japan of the long-acting inhaled neuraminidase inhibitor laninamivir. The actual submission is for CS-8958, a prodrug of laninamivir which is converted to the active molecule in the body.
You may also be interested in...
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.